Since there was no serious adverse event during the study, consistent with prior reports[23–25], our results proved that adding sitagliptin to insulin effectively and safely improves glycemic control and patients’ satisfaction in Japanese patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.